Public-registry site landscape for NCT02612558, a Warm Antibody Autoimmune Hemolytic Anemia study sponsored by Rigel Pharmaceuticals. All data below is from public sources; Eichor is not affiliated with the sponsor.
| Trial | NCT02612558 (registry record) |
| Sponsor | Rigel Pharmaceuticals |
| Condition(s) | Warm Antibody Autoimmune Hemolytic Anemia |
| Phase | PHASE2 |
| Listed sites | 36 |
| Site countries | United States, Canada |
Eichor generates a preliminary site-risk snapshot for NCT02612558 — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →